BD to Announce Financial Results for its First Quarter of Fiscal 2023
BD (Becton, Dickinson and Company) will release its financial results for the first quarter of fiscal year 2023 on February 2, 2023, at 6:30 a.m. ET. The results will cover the quarter ending on December 31, 2022, and will be available on their investor relations website. Following the release, management will host an audio webcast at 8 a.m. ET on the same day to discuss the financial results and company strategy. BD is recognized as a leading global medical technology company committed to enhancing healthcare through innovative solutions.
- Scheduled financial results release for Q1 2023 could signal transparency and investor engagement.
- Management's audio webcast allows direct communication about financial performance and strategy.
- None.
FRANKLIN LAKES, N.J., Jan. 5, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results for its first quarter of fiscal year 2023 on Thursday, February 2, 2023. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news release and presentation materials will include summary financial information for the company's first quarter of fiscal year 2023, which ended on Saturday, December 31, 2022.
BD management will host an audio webcast at 8 a.m. ET on February 2, 2023 to discuss its financial results and provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors and a replay will be available shortly after the call at the same website.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.
Contacts: | |
Media: | Investors: |
Troy Kirkpatrick | Francesca DeMartino |
VP, Public Relations | SVP, Head of Investor Relations |
858.617.2361 | 201.847.5743 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-to-announce-financial-results-for-its-first-quarter-of-fiscal-2023-301714958.html
SOURCE BD (Becton, Dickinson and Company)
FAQ
When will BD report its first quarter financial results for 2023?
What time will BD's financial results be released?
How can I access BD's financial results and presentation materials?
When is BD's audio webcast to discuss financial results?
